Consistent with this, clinical studies have reported a relationship between tumor‐infiltrating macrophages in epidermal growth factor receptor mutant NSCLC and shortened progression‐free survival (PFS) after initiation of immune checkpoint inhibitor treatment [11], and a relationship between tumor‐infiltrating M2 macrophages in NSCLC and shortened PFS after initiation of immune checkpoint inhibitor treatment [6]. This evidence concerns the gene EGFR and neoplasm.